to better understand current clinical challenges and the potential barriers to optimal care experienced by US hematologists and medical oncologists who treat patients with CML, ALL, or B-cell lymphomas. Findings from this assessment will help identify areas in which these specialists need to refect on their own practice and will help better inform the design and deployment of future continuing medical education activities and performance improvement interventions.
Methods
Tis assessment integrated the collection and analysis of qualitative and quantitative data deployed in 2 consecutives phases, in which an initial qualitative exploratory phase (March-May 2013) informed a subsequent quantitative confrmatory phase (May-June 2013) in a mixed-methods framework. 8 Te approach draws on the strengths of each phase: the depth of qualitative data and the analytic power of quantitative data collection. 8 Source triangulation was used to increase the validity and trustworthiness of fndings. 9 Triangulation consisted of combining diferent research methodologies (qualitative, quantitative) and different data collection methods (interviews, surveys). Two distinct independent ethical approvals (IRB Services, Boca Raton, FL for qualitative phase and Eisenhower Medical Center Institutional Review Board for quantitative phase) were obtained to ensure informed consent, protection, and confdentiality of participants, as per national guidelines and policies. 10 
Research tool design
A literature review and internal data from coauthors were used to generate hypotheses about gaps in knowledge, skills, and clinical confdence among US hematologists and medical oncologists. Hypotheses and consultation with 2 nationally recognized experts in hematologic malignancies informed the design of a 15-minute casebased online survey and a 45-minute, semistructured, interview guide. Te interviews focused on the challenges experienced by providers as they answered the case-based questions, and on the contextual and behavioral factors that infuence their clinical reasoning process. Findings from the qualitative phase and further consultation with experts informed the design of a 15-20 minute, online, quantitative survey deployed in phase 2 of the study. Te survey consisted of case vignettes, multiple choice questions, and semantic diferential rating scale questions (online fle 1).
Recruitment and data collection
Invitations to participate in both phases of the study were sent through email to a list of 11,696 hematologists and medical oncologists who were members of Clinical Care
Options. Invitations included a web link at which interested participants could learn about the study, sign a consent form, and answer eligibility questions before being redirected to complete the phase 1 or phase 2 survey.
A combination of criterion sampling and maximum variation sampling 11 was used to include a sample with a mix of years of practice and practice settings, ensuring a broad spectrum of perspectives on the reality of care. Eligible participants for the qualitative phase of the study had to be actively practicing in oncology in the United States, have a case load of at least 2 patients a year with CML, ALL, or B-cell lymphomas, and a minimum of 10 patients a year for all 3 conditions combined. In the quantitative phase, the case load inclusion criteria was reduced from 2 per condition to a combined total of at least 1 case a year to allow for identifcation of challenges in the group of practitioners most likely to be unfamiliar with these relatively rare diseases.
Analysis plan
A subset of transcribed interviews was coded and analyzed using NVivo qualitative data analysis software (QSR International Pty Ltd, Version 7, 2006) . Te qualitative analysis approach draws from the principles of both thematic analysis 12 and directed content analysis. 13 More specifcally, the approach included 4 steps: identifcation of predetermined codes, based on literature; coding of data based on step 1; analysis of data that could not be coded and refnement of coding tree; and identifcation of emerging themes with substantial data.
Te data collected from the online cases in phase 1 and from the quantitative survey in phase 2 were analyzed using SPSS 12.0 software (SPSS, Chicago, IL). Answers were compared with optimal or acceptable answers (as identifed by treatment guidelines [14] [15] [16] [17] and experts); differences between optimal and actual practice were considered to be a practice gap. 18 Triangulation of data was performed to link potential causalities reported in the interviews, to the practice performance gaps identifed from the quantitative phase. Subgroup diferences (by years of practice, practice types, or case load) were calculated using Pearson's chi-square test (hereafter referred to as chi-square).
Results

Sample size and demographics
For the qualitative phase of the study, 27 eligible physicians completed the case-based survey and were subsequently interviewed. For the quantitative phase of the study, 121 eligible respondents were included in the analysis. Sample demographics are presented in Table 1 . Respondents were evenly distributed for years of practice and represented a variety of practice settings, including academic medical centers (38%) and group or solo practices (34%). All of the respondents had at least 1% of their case load represented by the 3 malignancies combined, and more than half of the sample (53%) reported that patients with CML, ALL, or B-cell lymphomas represented more than 20% of their case load. Te samples of respondents from the qualitative and quantitative phases were not statistically signifcantly diferent from each other.
Identifed practice performance gaps A summary of the gaps identifed is included in online fle 2. Gaps most indicative of competencies needed for hematologists and medical oncologists to individualize treatment according to patient and tumor characteristics are detailed here. Qualitative quotes illustrating these gaps are included in online fle 3.
First-line treatment of chronic-phase CML
Tere was a discrepancy in the choice of frst-line tyrosine kinase inhibitor (TKI) therapy for chronic phase CML between the respondents' answers and those suggested by the expert faculty. Most of the respondents (62%) indicated that imatinib is their preferred frst-line therapy in this situation, whereas the faculty recommended dasatinib or nilotinib (Table 2, Question 1). Respondents from academic settings were signifcantly more likely to select nilotinib than were their colleagues from nonacademic settings (19% vs 10%, respectively; chisquare; P = .039). Te most frequently reported reason for the use of imatinib as frst-line therapy for chronic phase CML was that imatinib is still perceived as the standard of care and is the agent with which they have the most clinical experience.
When asked their level of agreement with the statement Early molecular responses to TKI therapy correlate with long-term clinical outcomes for patients with chronic phase CML, 33% of respondents selected the same level of agreement as the expert faculty (6 on a scale from 1 = strongly disagree to 7 = strongly agree), and 18% of respondents were in disagreement or neutral with the statement. For the statement Achieving a major molecular response (MMR) to TKI therapy substantially decreases the patient's risk of disease progression, 38% of respondents selected the same level of agreement as the expert faculty (7 on the same scale), and 13% of respondents were in disagreement or neutral with that statement.
Monitoring response to frst-line TKI therapy
When asked to describe their timing and frequency of cytogenetics by bone marrow biopsy to assess patient response to frst-line TKI therapy, a substantial proportion of respondents (74%) selected a higher frequency of bone marrow biopsies than recommended by the expert faculty (Table 2, Question 2). When asked to describe the timing and frequency of peripheral blood assessment of BCR-ABL transcripts by quantitative polymerase chain reaction (QPCR), 40% matched the expert response (Table 2, Question 3). A signifcant diference in response was observed by practice setting wherein a higher proportion of respondents from academic centers (52%) were aligned with the expert faculty's response, compared with those from nonacademic settings (31%; chi-square; P = .030).
Respondents' ability to interpret molecular and cytogenetic analyses to inform treatment decisions was assessed through the use of 8 diferent scenarios (Table  3 ). For 7 of the 8 assessments, level of respondent agreement with the study experts and guideline recommendations was less than 50%. For a patient whose monitoring results were BCR-ABL/ABL = 15% in the International Scale and 17/20 (Ph)-positive metaphases at 3 months, the expert faculty recommended that Sometimes a switch in therapy would be necessary in this scenario, whereas 40% of respondents indicated that they would rarely do so (Table 3 , clinical scenario A). Less experienced hematologists and medical oncologists were more likely to respond Rarely to that question compared with the more experienced physicians (56% vs 28%, respectively), whereas a higher proportion of those with more than 10
Continued on next page years of experience compared with those with less than 10 years of experience were aligned with faculty's answer (46% vs 24%; chi-square; P = .017). For clinical scenario G (Loss of CCyR at any time point), 75% of respondents with at least 10 cases of CML, ALL, and B-cell lymphomas a year were aligned with faculty's response and answered Definitely, while 39% of those with fewer than 10 cases a month agreed with the expert recommendation (chi-square; P = .037). Qualitative interviews revealed that many respondents did not understand the optimal timing of or how to read and interpret QPCR response data and therefore are challenged to determine when a change in therapy is indicated.
Terapeutic strategies to overcome TKI resistance
Te survey respondents were presented with 2 cases in which therapeutic strategies were needed to overcome imatinib resistance (Table 2 , Questions 4 and 5). For the scenario described in Question 5, that included a mutation for which multiple agents are expected to be efective, 34% of respondents selected the therapeutic strategy that was considered optimal for this patient by the faculty, and just over 60% selected one of the multiple treatment options recommended in treatment guidelines. Respondents from academic settings were more likely than those from nonacademic settings to have selected Switch therapy to nilotinib (28% vs 11%, respectively; chi-square; P = .018).
For the scenario described in Question 5 (a T315I mutation), 57% of respondents selected Switch therapy to ponatinib, and 10% selected allogeneic bone marrow transplantation for this scenario. Respondents from nonacademic settings were more likely than those from academic set- ACVBP-R, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone, plus rituximab; BMT, bone marrow transplantation; CCyR, complete cytogenic response; CHOP-R, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone, plus rituximab; CML, chronic myeloid leukemia; CP-CML, chronic phase chronic myeloid leukemia; CVAD, cyclophosphamide, vincristine, doxorubicin, examethoasone; CVP-R, cyclophosphamide, vincristine, prednisone, plus rituximab; EPOCH-R, etoposide, prednisone, oncovin, cyclophosphamide, hydroxydaunorubicin, plus rituximab; FISH, forescence in situ hybridization; MMR, mismatch repair; PET-CT, positron emission tomography-computed tomography; QPCR, quantitative polymerase chain reaction; R, rituximab; R-DHAP, rituximab plus dexamethasone, cytarabine, cisplatin; RICE, rituximab, ifosfamide, carboplatin, etoposide; SUV, standardized uptake value; TKI, tyrosine kinase inhibitor a Faculty best answers are shaded green; other acceptable answers shaded blue. One patient did not answer this question.
CASE B
n 55-year-old man with abdominal pain, vomiting, and a 30-pound weight loss n Was found to have a palpable large abdominal mass;
n Biopsy showed diffuse large B-cell lymphoma n PET-CT scan showed a 20-cm mass, retroperitoneal nodes, and a right iliac node with an SUV maximum of 20;
n Bone marrow was negative;
n Lactate dehydrogenase was twice the maximum normal;
n Patient promptly received 1 cycle of CHOP-R with resolution of symptoms and marked reduction in size of mass;
n Ki-67 of 90% and FISH studies showed a MYC rearrangement after drugs administration.
CASE C
n 70-year-old man;
n Just diagnosed with mantle cell lymphoma;
n Has involved nodes above and below the diaphragm and 10% involvement of the bone marrow.
tings to have selected Switch therapy to bosutinib (17% vs 2%, respectively; chi-square; P = .014); but more respondents from academic settings selected Switch therapy to ponatinib (76% vs 44%; chi-square; P = .001).
In phase I, more than 50% of respondents selected ponatinib for the patient scenario described in Question 5, when the T359I mutation was not specifcally mentioned as not being the more clinically relevant T315I. With the clarifcation added in the phase 2 survey, 12.4% selected ponatinib. Data from qualitative interviews indicated a lack of knowledge and understanding of how to interpret mutation reports in CML.
Individualizing frst-line therapy for patients with B-cell lymphomas
Te assays reported as most frequently requested by hematologists and medical oncologists to determine lymphoma subtype and molecular profle ( Figure 1 ) were, CD5 (87%), CD10 (84%), CD19 (83%), BCL-2 (83%) and the least frequently requested were CCND1 (44%), CD15 (50%), CD22 (65%), and ALK (68%). Tree of the assays were more frequently requested by respondents from academic settings compared with those in nonacademic settings: CD10: 100% vs 86% (chi-square; P = .011); CD30: 95% vs 80% (chi-square; P = .028); and MYC: 92% vs 70% (chi-square; P = .004). Participants were asked questions about potential change in frst-line therapy for a patient with difuse large B-cell lymphoma (DLBCL) initially started on CHOP-R (cyclophosphamide, hydroxydaunorubicin, oncovin , prednisone -rituximab; Table 2 , Questions 6-8). In Question 6, the patient scenario included an activated B-cell lymphoma genotype and 29% agreed with the expert recommendation to add bortezomib to CHOP-R. In Question 7, with both MYC and BCL-2 rearrangements included, 40% agreed with faculty recommendation to switch to EPOCH-R (etoposide, prednisone, vincristine, and doxorubicin hydrochloride -rituximab) and consider an autologous bone marrow transplant in frst complete remission. In Question 8, a new scenario was explored for a patient with symptomatic mantle cell lymphoma. CHOP-R was selected as initial therapy for this patient by 46% of the participants; whereas the expert recommendation was bendamustine and rituximab (32% of respondents indicated that they would use this regimen). Qualitative interviews indicated that respondents were confused about indications and clinical data for therapies other than CHOP-R for patients with DLBCL or mantle cell lymphoma.
Mechanisms of action for promising new agents
Survey respondents were asked to match the generic names of 9 agents to their molecular target and only one, temsirolimus, was correctly matched to its molecular target by over 80% of the respondents (Figure 2 ). Only 2 other agents (brentuximab vedotin and afibercept) had their targets correctly identifed by over 60% of respondents. Five of the agents were correctly matched with their targets by less than a third of the participants. In addition, 65% of respondents got less than half of the answers correct, and only 7% correctly matched all 9 agents to their molecular target. Respondents with fewer than 10 CML, ALL, B-cell lymphoma cases a year had a mean of 28% correct answers, compared with a 45% mean for those with more than 10 cases per year.
Discussion
Te challenges highlighted here are likely to refect those faced by most hematologists and medical oncologists in the United States. Te following discussion will demonstrate how knowledge and competency gaps could impact clinical efciencies and patient outcomes and how practicing specialists, especially those who are community-based, can refect on the existence of these gaps in their own practice. Table 4 provides questions that, based on the results of this study, could form the basis for clinical self-assessment, facilitating identifcation by hematologists and medical oncologists of their own clinical gaps, possibly leading them to seek educational strategies that could improve clinical efciencies and patient outcomes.
When making frst-line treatment choices for CML, hematologists and medical oncologists reported that they rely heavily on their previous experience with imatinib, suggesting that new data is not consistently being integrated into community practice. More specifcally, new data indicates that early molecular response to TKI therapy is signifcantly associated with long-term survival outcomes, 19, 20 and that the second-generation TKIs (bosutinib, dasatinib, nilotinib) are superior to imatinib in relation to early efcacy responses .14,21-23 A better awareness and understanding of such data, through targeted education and expert guidance, may improve outcomes for patients with newly diagnosed chronic phase CML.
Many community specialists encounter a limited number of CML cases annually and therefore, assaying and interpreting response to frst-line TKI therapy is challenging. Until recently, bone marrow cytogenetic analysis had been the gold standard for monitoring response to TKI therapy in chronic phase (CP-) CML. However, more experts and guideline recommendations have begun to rely on molecular responses by QPCR from peripheral blood every 3 months as important milestones for response and predicting long-term outcomes for their patients. 14, 24, 25 Tis study indicates that bone marrow cytogenetic analysis is being used more frequently than recommended. Te overuse of invasive bone marrow cytogenetic analysis could have multiple consequences to patient quality of life, patient adherence to their recommended monitoring schedule, and use of resources and cost to health care systems.
Tese fndings suggest that most hematologists and medical oncologists are misaligned with expert-recommended practice on when to suggest a change in TKI therapy. NCCN14 and ELN17 Guidelines recommend con- sideration of a therapeutic change if BCR-ABL/ABL is > 10% on the International Scale at 3 or 6 months. Findings from the study suggest that this recommendation is not well integrated by hematologists and oncologists in the United States because almost half of the respondents would not consider a change in therapy for a patient with BCR-ABL/ABL of 15% on the International Scale and 17/20 Ph-positive metaphases at 3 months. Te subgroup diference observed in relation to the hematologic case load of the participants exemplifes how rareness of the disease impedes adoption of best practices. Guidelines recommend performing mutational analysis in the context of poor response to frst-line therapy likely due to secondary TKI resistance and suggest that the choice of therapeutic strategy to overcome TKI resistance should be based in part on the results of a mutation analysis. 14, 17, 24 Findings from this study indicate that a substantial proportion of hematologists and medical oncologists are challenged to interpret mutational analysis reports and to select second-line or salvage therapy. Many community specialists do not fully understand that the available TKIs have unique resistance profles and that some mutations (other than T315I) may prompt selection of a particular TKI. However, many BCR-ABL mutations do not instill resistance to available TKIs. Terefore education is needed to reinforce that a stem cell transplant is likely unnecessary following failure of frst-line therapy for patients with CP-CML and that for mutations other than T315I, treatment options besides ponatinib may also overcome secondary TKI resistance.
Te results from this national assessment indicate that CHOP-R combination chemotherapy is still the standard choice for newly diagnosed patients with aggressive B-cell lymphomas in many practices despite growing evidence for individualized approaches for diferent subpopulations of patients with biologically distinct variants. 16, 26, 27 For example, translocations that target the oncogenes MYC and BCL2 have been consistently reported and there is consensus that MYC translocations with or without BCL2 (so-called double-hit mutations) confer a worse prognosis in patients with DLBCL who are treated with CHOP-R .26,28 Phase 3 clinical trial data indicate that the combination of bendamustine and rituximab is likely to be better tolerated and more efective than CHOP-R for patients with mantle cell lymphoma and both CHOP-R and bendamustine and rituximab are recommended in the NCCN guidelines. 16 Findings suggest that a key part of treatment decisionmaking related to patients with ALL and B-cell lymphomas is often empirical, largely relying on clinical experience with each treatment option. Although balancing risks and benefts is always part of the art of medicine, this study indicates that many community hematologists and medical oncologists are not individualizing therapy for patients with ALL and B-cell lymphomas, potentially explaining the variability in their patients' response.
A lack of knowledge of the unique mechanisms of action of emerging experimental agents for hematologic malignancies may help explain why, despite guidelines recommending clinical trials for patients with relapsed or refractory ALL and B-cell lymphomas, enrollment in clinical trials for these tumors remain low. Furthermore, this trend may be even more pronounced in these diseases as many patients are either young adults or elderly.29 Moreover, a lack of familiarity with generic names, mechanisms of action, and biologic rationale for use may lead to missed opportunities to enroll eligible patients in clinical trials. Of more importance, hematologists and medical oncologists Answers to the 9 questions asking participants to match the therapeutic agent with its target (n = 121). Only 2 other agents (brentuximab vedotin and afibercept) had their targets correctly identifed by more than 60% of respondents.
without a complete understanding of these agents will lack competence to efectively apply emerging clinical trial data and agents with new indications into their clinical practice.
Limitations
Self-selection bias was a possibility, as participation in the study was voluntary, but the use of purposive sampling improves the probability of having a sample that is representative of the targeted population. 11 A subset of participants (n = 71) from which demographic information was incomplete was removed from the analysis to avoid inclusion of potentially noneligible participants. All results are based on self-report by the participants and the relation to actual practice is assumed. Optimally, these results would be compared to chart-level data. In the future it will be interesting to see if these data are refected in treatment databases.
Conclusions
Tis study has identifed important areas of practice where performance gaps among US hematologists and medical oncologists may be hindering delivery of optimal care to patients with CML, ALL, or B-cell lymphomas. Two common points across the fndings presented here raise questions that go beyond the precise clinical points tested. First, it illustrates the increasing complexity of treatment decisions as more treatment options become available. Second it raises the question of how physicians can stay current on specifc low prevalence diseases that represent a small percentage of their case load.
Our fndings should be considered in the design of continuing professional development and educational programs. In addition, within the context of the US PPACA, which increases pressure for greater efciency in the delivery of healthcare services, our fndings could stimulate selfrefection among community hematologists and medical oncologists on knowledge or competency gaps that may exist in their own practice, and incite them to deploy local educational and performance improvement strategies.
